ProfileGDS5672 / 214542_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [HG-U133_Plus_2]
OrganismHomo sapiens


control bevacizumab dibenzazepine GSM958322 GSM958323 GSM958324 GSM958328 GSM958329 GSM958330 GSM958325 GSM958326 GSM958327 58% 58% 57% 56% 57% 57% 57% 52% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM958322U87-EV human glioblastoma xenograft - Control - 1 [HG-U133_Plus_2]3.7738958
GSM958323U87-EV human glioblastoma xenograft - Control - 2 [HG-U133_Plus_2]3.6603458
GSM958324U87-EV human glioblastoma xenograft - Control - 3 [HG-U133_Plus_2]3.6109957
GSM958328U87-EV human glioblastoma xenograft - Bevacizumab treated - 1 [HG-U133_Plus_2]3.4680256
GSM958329U87-EV human glioblastoma xenograft - Bevacizumab treated - 2 [HG-U133_Plus_2]3.6109957
GSM958330U87-EV human glioblastoma xenograft - Bevacizumab treated - 3 [HG-U133_Plus_2]3.5572357
GSM958325U87-EV human glioblastoma xenograft - dibenzazepine treated - 1 [HG-U133_Plus_2]3.6235457
GSM958326U87-EV human glioblastoma xenograft - dibenzazepine treated - 2 [HG-U133_Plus_2]3.1495952
GSM958327U87-EV human glioblastoma xenograft - dibenzazepine treated - 3 [HG-U133_Plus_2]3.6109957